Skip to main content

Priorix FDA Approval History

Last updated by Judith Stewart, BPharm on June 8, 2022.

FDA Approved: Yes (First approved June 3, 2022)
Brand name: Priorix
Generic name: measles, mumps, and rubella virus vaccine, live
Dosage form: Injection
Company: GlaxoSmithKline
Treatment for: Measles Prophylaxis, Mumps Prophylaxis, Rubella Prophylaxis

Priorix (measles, mumps, and rubella virus vaccine, live) is a live attenuated vaccine for use in active immunization against infection by measles, mumps and rubella (MMR).

  • Priorix becomes an additional source of measles, mumps and rubella vaccine for U.S. patients in addition to M-M-R II.
  • Priorix was first registered in Germany in 1997 and is currently licensed outside the U.S. in over 100 countries worldwide.
  • Priorix is administered via subcutaneous injection.
    • The first dose is administered at 12 through 15 months of age.
    • The second dose is administered at 4 through 6 years of age.
  • In clinical studies, the efficacy of Priorix was demonstrated based on comparative immunogenicity data with M-M-R II.
  • Common adverse reactions include pain, redness, swelling, loss of appetite, irritability, drowsiness, and fever. 

Development timeline for Priorix

DateArticle
Jun  6, 2022Approval FDA Approves Priorix (Measles, Mumps and Rubella Vaccine, Live) for the Prevention of Measles, Mumps and Rubella in Individuals 12 Months of Age and Older
Aug  2, 2021GSK Files for Licensure of Priorix MMR Vaccine in the US

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.